Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures

Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases. We have determined the X‐ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chemical classes. Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly‐rich loop, helix C, the DFG sequence, and activation loop. The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homology 2‐kinase domain linker. Two novel activation loop conformations and an atypical DFG conformation are observed representing unique inactive states of BTK. Two regions within the activation loop are shown to structurally transform between 310‐ and α‐helices, one of which collapses into the adenosine‐5′‐triphosphate binding pocket. The first crystal structure of a Tec kinase family member in the pharmacologically important DFG‐out conformation and bound to a type II kinase inhibitor is described. The different protein conformations observed provide insights into the structural flexibility of BTK, the molecular basis of its regulation, and the structure‐based design of specific inhibitors.

[1]  P. Caron,et al.  Classifying protein kinase structures guides use of ligand‐selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex , 2007, Proteins.

[2]  J. M. Bradshaw,et al.  Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase* , 2007, Journal of Biological Chemistry.

[3]  A. Kuglstatter,et al.  Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. , 2010, Journal of medicinal chemistry.

[4]  L. Silvian,et al.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases , 2010, Protein science : a publication of the Protein Society.

[5]  F. Uckun,et al.  Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* , 1999, The Journal of Biological Chemistry.

[6]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .

[7]  Jim W Barnett,et al.  Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes , 2009, Chemical biology & drug design.

[8]  F. Uckun,et al.  Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.

[9]  A. Kuglstatter,et al.  Crystal Structures of IL‐2‐inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation , 2010, Chemical biology & drug design.

[10]  F. Uckun,et al.  Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity , 2010, Expert opinion on therapeutic patents.

[11]  Paul R. Gerber,et al.  Peptide mechanics: A force field for peptides and proteins working with entire residues as smallest units , 1992 .

[12]  T. Wirth,et al.  Bruton's Tyrosine Kinase is involved in innate and adaptive immunity. , 2005, Histology and histopathology.

[13]  D. Fabbro,et al.  Structural biology contributions to tyrosine kinase drug discovery. , 2009, Current opinion in cell biology.

[14]  Jessica M. Lindvall,et al.  Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling , 2005, Immunological reviews.

[15]  Z. Pan Bruton's tyrosine kinase as a drug discovery target. , 2008, Drug news & perspectives.

[16]  D. Rotstein,et al.  Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. , 2006, Journal of medicinal chemistry.

[17]  O. Witte,et al.  Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. , 2006, International immunology.

[18]  D. Payan,et al.  R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[19]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[20]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[21]  Robert M. Sweet,et al.  Macromolecular Crystallography: Part A , 1997 .

[22]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[23]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[24]  P. Norman A novel Syk kinase inhibitor suitable for inhalation: R-343(?) – WO-2009031011 , 2009, Expert opinion on therapeutic patents.

[25]  C. Toniolo,et al.  The polypeptide 310-helix. , 1991, Trends in biochemical sciences.